Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-05-17
2005-05-17
Carlson, Karen Cochrane (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000, C530S350000, C435S007100, C435S007600, C435S007800, C435S068100, C435S069400, C435S070100, C514S056000
Reexamination Certificate
active
06894022
ABSTRACT:
Proteins are incorporated into protein or polysaccharide matrices for use in tissue repair, regeneration and/or remodeling, and/or drug delivery. The proteins can be incorporated so that they are released by degradation of the matrix, enzymatic action, and/or diffusion. In one embodiment, a fusion protein, which contains a crosslinking region, such as a factor XIIIa substrate, and a native protein sequence, such as a bioactive factor, is constructed. Degradable linkages may be included between the crosslinking region and the bioactive factor.
REFERENCES:
patent: 4613665 (1986-09-01), Larm
patent: 4810784 (1989-03-01), Larm
patent: 5100668 (1992-03-01), Edelman
patent: 5171670 (1992-12-01), Kronenberg et al.
patent: 5202247 (1993-04-01), Kilburn
patent: 5504001 (1996-04-01), Foster
patent: 5529986 (1996-06-01), Larsson et al.
patent: 5561982 (1996-10-01), Tunkel et al.
patent: 5582862 (1996-12-01), Reed
patent: 5641670 (1997-06-01), Treco et al.
patent: 5693341 (1997-12-01), Schroeder et al.
patent: 5773577 (1998-06-01), Cappello
patent: 5840837 (1998-11-01), Krstenansky et al.
patent: 5874308 (1999-02-01), Kilburn et al.
patent: 6331422 (2001-12-01), Hubbell et al.
patent: 6468731 (2002-10-01), Hubbell et al.
patent: 200 10 297 (2000-08-01), None
patent: WO 9202620 (1992-02-01), None
patent: WO 9523611 (1995-09-01), None
patent: WO 0064481 (2000-11-01), None
Jeong, J.-M. et al. (1995) The fibronectin-binding domain of transglutaminase. J. Biol. Chem. vol. 270, pp. 5654-5658.*
Yamada, K. M. et al. (1980) Characterization of fibronectin interactions with glycosaminoglycans and identification of active proteolytic fragments. J. Biol. Chem. vol. 255, pp. 6055-6063.*
Monsonego, A. et al. (1998) Factor XIIIa as a nerve-associated transglutaminase. FASEB J. vol. 12, pp. 1163-1167.*
Jyon, M. et al. (1997) The interaction of the transforming growth factor-betas with heparin/heparan sulfate is isoform-specific. J BIol Chem. vol. 272, pp. 18000-18006.*
Rogers, et al., “Neuron-specific interactions with two neurite-promoting fragments of fibronectin,”J. Neurosci.5(2):369-78 (1985).
Sakiyama, et al., “Incorporation of heparin-binding peptides into fibrin gets enhances neurite extension: an example of designer matrices in tissue engineering,”FASEB. J.13(15):2214-24 (1999).
Sakiyama-Elbert, et al., “Development of fibrin derivatives for controlled release of heparin-binding growth factors,”J. Controlled Release65(3):389-402 (2000).
Schense, et al., “Cross-linking exogenous bifunctional peptides into fibrin gels with factor XIIIa,”Bioconjug. Chem.10(1):75-81 (1999).
Seibel, et al., “Transfection of mitochondria: strategy towards a gene therapy of mitochondrial DNA disease,”Nucleic Acids Res.23(1):10-7 (1995).
Sellke, et al., “Basic FGF enhances endothelium-dependent relaxation of the collateral-perfused coronary microcirculation,”Am. J. Physiol.267(4 pt 2):H1303-11 (1994).
Smith, et al., “Rapid identification of highly active and selective substrates for stromelysin and matrilysin using bacteriophage peptide display libraries,”J. Biol. Chem.270(12):6440-9 (1995).
Spillman, et al., “Defining the interleukin-B-binding domain of heparan sulfate,”J. Biol. Chem.273(25):15487-93 (1998).
Steffen, et al., “Characterization of cell-associated and soluble forms of connective tissue growth factor (CTGF) produced by libroblast cell sin vitro,”Growth Factors15(3):199-213 (1998).
Giannelli, et al., “Transforming growth factor-beta 1 triggers hepatocellular carcinoma invasiveness via alpha3beta 1 integrin,”Am. J. Pathol.161(1):183-193 (2002).
Ludbrook, et al., “The integrin alphavbeta3 is a receptor for the latency-associated peptides of transforming growth factors beta1 and beta 3,”Biochem. J.389(2): 311-318 (2003).
Nesti, et al., “TGF-beta 1 calcium signaling increases alpha5 integrin expression in ostecblasts,”J. Orthop. Res.20(5): 1042-1049 (2002).
Rout, et al., “Transforming growth factor-beta1 modulates expression of adhesion and cytoskeletal proteins in human peritoneal fibroblasts,”Fertil. Steril.78(1):154-161 (2002).
Swiss-Prot Primary Accession No. PO2751, Entry name FINC_HUMAN (1966).
Swiss-Prot Primary Accession NO. PO1137, Entry name TGF1_HUMAN (1986).
Besson, et al., “Synthetic peptide substrates for a conductimetric assay of Pseudomonas aeruginosa elastase,”Anal. Biochem.237(2):216-23 (1996).
Borrajo, et al., “Derivatized Cyclodextrins as peptidometics: Influence on Neurite Growth,”Bioorganic and Medicinal Chemistry Letters7:1185-90 (1997).
Coombs, et al. “Directing sequence-specific proteolysis to new targets. The influence of loop size and target sequence on selective proteolysis by tissue-type plasminogen activator and urokinase-type plasminogen activator,”J. Biol. Chem.273(8):4323-8 (1998).
Dimilla, et al., “Mathematical model for the effects of adhesion and mechanics on cell migration speed,”Biophys. J.60(1):15-37 (1991).
Dinbergs, et al., “Cellular response to transforming growth factor-beta1 and basic fibroblast growth factor depends on release kinetics and extracellular matrix interactions,”J. Biol. Chem.271(47):29822-9 (1996).
Edelman, et al., “Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vase vasorum in injured rat arteries,”J. Clin. Invest.89(2):465-73 (1992).
Edelman, et al., “Controlled and modulated release of basic fibroblast growth factor,”Biomaterials.12(7):619-26 (1991).
Edelman, et al., “Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition,”Proc. Natl. Acad. Sci. U. S. A.90(4):1513-7 (1993).
Edgar, et al., “The heparin-binding domain of laminin is responsible for its effects of neurite outgrowth and neuronal survival,”EMBO J.3(7):1463-8 (1984).
Götz, et al., “Neurotrophin-6 is a new member of the nerve growth factor family,”Nature372(6503):266-9 (1994).
Grainger, et al., “Poly(dimethylsiloxane)-poly(ethylene oxide)-heparin block copolymers. I. Synthesis and characterization,”J. Biomed. Mater. Res.22(3):231-49 (1988).
Harada, et al., “Basic fibroblast growth factor improves myocardial function in chronically ischemica porcine hearts,”J. Clin. Invest.94(2):623-30 (1994).
Hata, et al., “Binding of lipoprotein lipase to heparin. Identification of five critical residues in two distinct segments of the amino-terminal domain,”J. Biol. Chem.268(12):8447-57 (1993).
Haugen, et al, “Central and peripheral neurite outgrowth differs in preference for heparin-binding versus integrin-binding sequences,”J. Neurosci.12(6):2034-42 (1992).
Herbert, et al., “Effects of fibinolysis on neurite growth from dorsal root ganglia cultured in two- and three- dimensional fibrin gels,”J. Comp. Neurol.365(3):380-91 (1996).
Herbert, et al., “Effects of fibrin micromorphology on neurite growth from dorsal root ganglia cultured in three- dimensional fibrin gels,”J. Biomed. Mater. Res.40(4):551-9 (1998).
Kallapur, et al, “The neural cell adhesion molecular (NCAM) heparin binding domain binds to cell surface heparan sulfate proteoglycans,”J. Neurosci. Res.33(4):538-48 (1992).
Kaneda, et al., “Midkine, a heparin-binding growth/differentiation factor, exhibits nerve cell adhesion and guidance activity for neurite outgrowth in vitro,”J. Biochem.119(6):1150-6 (1996).
Kiguchi, et al., “Altered expression of epidermal growth factor receptor ligands in tumor promoter-treated mouse epidermis and in primary mouse skin tumors induced by an initiation-promotion protocol,”Mol. Carcinog.22(2):73-83 (1998).
Kinosaki, et al., “Identification of heparin-binding stretches of a naturally occurring deleted variant of hepatocyte growth factor (dHGF),”Biochim
Hubbell Jeffrey A.
Sakiyama-Elbert Shelly E.
Schense Jason C.
Carlson Karen Cochrane
Eidgenossische Technische Hochschule Zurich
Liu Samuel Wei
Pabst Patent Group LLP
Universitat Zurich
LandOfFree
Growth factor modified protein matrices for tissue engineering does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Growth factor modified protein matrices for tissue engineering, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Growth factor modified protein matrices for tissue engineering will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3401966